"I am writing to convey my concern over the Texas Department of Health's
attempt to prevent the Burzynski Research Institute (BRI) from using
antineoplastons on its patients. The Texas Medical Practices Act recognized
an appropriate role of experimental drugs and drug combinations in the treatment
of terminal diseases.
"Section 5.09 of this Act states: `a physician licensed to practice medicine
under this Act may supply patients with any drugs, remedies, or clinical
supplies as are necessary to meet the patients' immediate needs.' Seeking
a permanent injunction against BRI's antineoplaston therapy is in direct
conflict with this provision.
"Prominent oncologists at leading cancer centers across the country have
examined the records of BRI's patients and acknowledge that the antineoplaston
therapy is having beneficial effects. If successful in its lawsuit against
BRI, the state of Texas will deny these patients the only treatment which
as having any positive effect. In my opinion, this would be a tragedy."
"While still experimental, antineoplastons are poised to enter the FDA approval
process. I urge you to delay any further action against BRI..."
Ralph W. Moss, Ph.D. is the author of eight books and three documentaries
on cancer-related topics. He is an advisor on alternative cancer treatments
to the National Institutes of Health, Columbia University, and the University
of Texas. He researches and writes individualized "Healing Choices" reports
for people with cancer. For information on Healing Choices, you can contact
coordinator Anne Beattie @ 144 St. John's Place, Brooklyn, NY 11217; Phone
718-636-4433; Fax 718-636-0186.